Therapy-induced APOBEC3A drives evolution of persistent cancer cellsHideko Isozaki, Aaron N. Hata|Nature|2023Cited by 143
Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine KinasesHideko Isozaki, Katsuyuki Kiura|Cancer Research|2016Cited by 128